ASH 2020 – CLL: Wrap-Up

In pretreated, high-risk patients with relapsed or refractory chronic lymphocytic leukemia (CLL), treatment with lisocabtagene maraleucel (liso-cel) resulted in a high rate of undetectable minimal residual disease. Responses to treatment with liso-cel were rapid and durable, without late or delayed adverse events of concern. Read More ›

The noncovalent BTK inhibitor LOXO-305 demonstrated promising efficacy in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LOXO-305 was well-tolerated and active in patients following multiple prior lines of therapy, including patients with and without BTK C481 mutations. Read More ›

Treatment with CD19-CAR T-cells in patients with chronic lymphocytic leukemia (CLL) and disease transformation was found to be safe and demonstrates a high rate of complete remission. Read More ›

The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Read More ›

The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL. Read More ›

Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

Combination ibrutinib plus venetoclax treatment results in sustained response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This response is sustained despite planned discontinuation in patients who had achieved minimal residual disease. Read More ›

Individual clonal growth rates can be used to estimate the minimal residual disease doubling time after fixed-duration treatment. Clonal growth rates were lower after treatment with venetoclax-obinutuzumab when compared with chlorambucil-obinutuzumab. Read More ›

The combination regimen of thalidomide, prednisone, and methotrexate demonstrated greater efficacy than treatment with cyclosporine and prednisone in patients with large granular lymphocytic leukemia and with limited adverse events. Read More ›

Two-year fixed-duration treatment with venetoclax-rituximab demonstrates durable response, with a substantial proportion of patients retaining undetectable minimal residual disease 36 months after treatment cessation. Read More ›

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice

Learn more about our family of publications.

View Our Publications